Retinal pigment epithelial tear after intravitreal ranibizumab for subfoveal CNV secondary to AMD.
OBJECTIVE
To report a case of retinal pigment epithelial tear following intravitreal ranibizumab injection for subfoveal choroidal neovascularization.


METHODS
Retrospective single case review.


RESULTS
A 78-year-old Caucasian female was treated with intravitreal ranibizumab for occult subfoveal choroidal neovascularization (CNV) from age-related macular degeneration (AMD). She returned for evaluation with decreased vision and was found to have a retinal pigment epithelial tear on biomicroscopy. Fluorescein angiography and OCT testing confirmed the clinical findings.


CONCLUSIONS
Although a pigment epithelial tear in neovascular AMD can represent natural history, prior reports of such tears after thermal laser, photodynamic therapy with verteporfin and following intravitreal injection of pegaptanib Na combined with this case report suggest that clinicians should be aware of and monitor patients for the possibility of this complication after intravitreal injections of ranibizumab.
Apte
Rajendra S
RS
Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, 660 South Euclid Avenue, Box 8096, St. Louis, MO 63110, USA. apte@vision.wustl.edu
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D005260:Female; D005654:Fundus Oculi; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000150:complications; D010857:Pigment Epithelium of Eye / Q000187:drug effects* / Q000473:pathology; D000069579:Ranibizumab; D012167:Retinal Perforations / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D041623:Tomography, Optical Coherence; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab